Paroxysmal supraventricular tachycardia drug of choice
Paroxysmal supraventricular tachycardia drug of choice Paroxysmal supraventricular tachycardia (PSVT) is a common type of arrhythmia characterized by sudden episodes of rapid heart rate originating above the ventricles. These episodes can be unsettling and occasionally hemodynamically significant, especially in vulnerable populations. Effective management of PSVT hinges on prompt termination of acute episodes and long-term prevention strategies, with pharmacotherapy playing a central role in both aspects.
Paroxysmal supraventricular tachycardia drug of choice The first line of treatment for an acute PSVT episode often involves vagal maneuvers. Techniques such as the Valsalva maneuver or carotid sinus massage increase vagal tone, which can temporarily slow conduction through the atrioventricular (AV) node and terminate the arrhythmia. When these are ineffective, pharmacologic agents become necessary. Among these, adenosine is widely regarded as the drug of choice for acute PSVT due to its rapid onset, high efficacy, and short half-life, which allows for quick cessation of adverse effects.
Paroxysmal supraventricular tachycardia drug of choice Adenosine acts predominantly on the AV node by activating A1 receptors, leading to transient AV nodal blockade. This effectively interrupts reentrant circuits involving the AV node, which are common in PSVT. Typically administered as a rapid intravenous bolus of 6 mg, it often restores sinus rhythm within seconds. If the initial dose fails, a second dose of 12 mg may be given. Due to its potent and short-lived action, adverse effects are usually transient and include flushing, chest discomfort, and brief asystole.
For patients who do not respond to adenosine or have contraindications such as asthma or certain heart blocks, other pharmacologic options are considered. Calcium channel blockers like verapamil or diltiazem are effective in controlling acute episodes by slowing conduction through the AV node. These agents are particularly useful when adenosine is contraindicated or unavailable but require careful monitoring due to potential side effects like hypotension or bradycardia.
Paroxysmal supraventricular tachycardia drug of choice In addition to acute management, preventing recurrent episodes of PSVT involves the use of medications with long-term efficacy. Beta-blockers, such as metoprolol or propranolol, are commonly employed to reduce sympathetic stimulation and decrease the likelihood of episodes. They are generally well-tolerated and provide both rate control and prophylaxis. Calcium channel blockers can also be used chronically for prevention, especially in patients who cannot tolerate beta-blockers.
In some cases, if medication fails to control symptoms or episodes become frequent and debilitating, interventional procedures like catheter ablation may be considered. This procedure can effectively eliminate the accessory pathways responsible for reentry, providing a potentially curative solution. Paroxysmal supraventricular tachycardia drug of choice
In summary, adenosine remains the drug of choice for the acute management of PSVT due to its rapid action and high efficacy. Long-term management often involves beta-blockers or calcium channel blockers to prevent recurrences, with procedural options as a definitive solution in refractory cases. Proper understanding and timely intervention are crucial for improving patient outcomes and quality of life. Paroxysmal supraventricular tachycardia drug of choice